Vistagen Therapeutics (MEX:VTGN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
40 GF Score
Price MXN10.65
GF Value MXN33.38
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vistagen Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:VTGN vs PLUR, PTN, CLRB: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


MEX:VTGN
40GF Score
Vistagen Therapeutics Inc MEX:VTGN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of MXN10.65 is trading 68.1% below its estimated GF Value™ of MXN33.38.

Key valuation signals for MEX:VTGN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: MXN33.38 vs. price of MXN10.65 (68.1% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for MEX:VTGN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price
MXN33.38
GF Value